Low-dose Interleukin-2 in Combination With Standard Therapy on Idiopathic Inflammatory Myopathy
Status:
Not yet recruiting
Trial end date:
2021-04-08
Target enrollment:
Participant gender:
Summary
This study aims to explore the clinical and immunological efficacy of low-dose Interleukin-2
(IL-2) and cyclosporin a (CSA) on idiopathic inflammatory myopathy (IIM)